BeiGene | A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

⟵ Back to Search Results

A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

Beigene Study ID

BGB-21447-101

ClinicalTrials.gov ID

NCT05828589

Study Overview

Sex: All

Age: 18 Years / N/A

No Study Documents

Locations

Study Overview

Sex: All

Age: 18 Years / N/A

No Study Documents